Page 117 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

96 PART I The Biology and Pathogenesis of Cancer

75. Sonnenschein EG, Glickman LT, Goldschmidt MH, et al.: Body 98. Bossuyt PM, Reitsma JB, Bruns DE, et al.: Towards complete and
conformation, diet, and risk of breast cancer in pet dogs: a case- accurate reporting of studies of diagnostic accuracy: the STARD
control study, Am J Epidemiol 133:694–703, 1991. initiative. Standards for reporting of diagnostic accuracy, Clin
VetBooks.ir 76. Ru G, Terracini B, Glickman LT: Host related risk factors for 99. Gardner IA: Quality standards are needed for reporting of test
Chem 49:1–6, 2003.
canine OSA, Vet J 156:31–39, 1998.
77. Teske E, Naan EC, van Dijk EM, et al.: Canine prostate carcinoma:
epidemiological evidence of an increased risk in castrated dogs, Mol accuracy studies for animal diseases, Prev Vet Med 97:136–143,
2010.
Cell Endocrinol 197:251–255, 2002. 100. Webster JD, Dennis MM, Dervisis N, et al.: Recommended guide-
78. Bryan JN, Keeler MR, Henry CJ, et al.: A population study of lines for the conduct and evaluation of prognostic studies in veteri-
neutering status as a risk factor for canine prostate cancer, Prostate nary oncology, Vet Pathol 48:7–18, 2011.
67:1174–1181, 2007. 101. Lawrence J, Rohren E, Provenzale J: PET/CT today and tomorrow
79. Torres de la Riva G, Hart BL, Farver TB, et al.: Neutering dogs: in veterinary cancer diagnosis and monitoring: fundamentals, early
effects on joint disorders and cancers in Golden Retrievers, PLoS results and future perspectives, Vet Comp Oncol 8:163–187, 2010.
One 8:e55937, 2013. 102. Chou R, Croswell JM, Dana T, et al.: Screening for prostate cancer:
80. Zink MC, Farhoody P, Elser SE, et al.: Evaluation of the risk and a review of the evidence for the U.S. Preventive Services Task Force,
age of onset of cancer and behavioral disorders in gonadectomized Ann Intern Med 155:762–771, 2011.
Vizslas, J Am Vet Med Assoc 244:309–319, 2014. 103. Sargeant JM, Thompson A, Valcour J, et al.: Quality of reporting
81. Hart BL, Hart LA, Thigpen AP, et al.: Long-term health effects of of clinical trials of dogs and cats and associations with treatment
neutering dogs: comparison of Labrador Retrievers with Golden effects, J Vet Intern Med 24:44–50, 2010.
Retrievers, PLoS One 9:e102241, 2014. 104. Vail DM: Cancer clinical trials: development and implementation,
82. Johnston SD, Kamolpatana K, Root-Kustritz MV, et al.: Prostatic Vet Clin North Am Small Anim Pract 37:1033–1057, 2007.
disorders in the dog, Anim Reprod Sci, 2000. 60-61:405–415. 105. London CA, Malpas PB, Wood-Follis SL, et al.: Multi-center, placebo-
83. Perez Alenza MD, Pena L, del Castillo N, et al.: Factors influencing controlled, double-blind, randomized study of oral toceranib phosphate
the incidence and prognosis of canine mammary tumours, J Small (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of
Anim Pract 41:287–291, 2000. dogs with recurrent (either local or distant) mast cell tumor following
84. Heinlein CA, Chang C: Androgen receptor in prostate cancer, surgical excision, Clin Cancer Res 15:3856–3865, 2009.
Endocr Rev 25:276–308, 2004. 106. Rau SE, Barber LG, Burgess KE: Efficacy of maropitant in the
85. Gann PH, Hennekens CH, Ma J, et al.: Prospective study of sex prevention of delayed vomiting associated with administration of
hormone levels and risk of prostate cancer, J Natl Cancer Inst doxorubicin to dogs, J Vet Intern Med 4:1452–1457, 2010.
88:1118–1126, 1996. 107. Scott MC, Sarver AL, Gavin KJ, et al.: Molecular subtypes of osteo-
86. Sorenmo KU, Goldschmidt M, Shofer F, et al.: Immunohisto- sarcoma identified by reducing tumor heterogeneity through an
chemical characterization of canine prostatic carcinoma and cor- interspecies comparative approach, Bone 49:356–367, 2011.
relation with castration status and castration time, Vet Comp Oncol 108. Modiano JF, Breen M, Burnett RC, et al.: Distinct B-cell and T-cell
1:48–56, 2003. lymphoproliferative disease prevalence among dog breeds indicates
87. Navarro D, Luzardo OP, Fernandez L, et al.: Transition to andro- heritable risk, Cancer Res 65:5654–5661, 2005.
gen-independence in prostate cancer, J Steroid Biochem Mol Biol 109. Akesson A, Julin B, Wolk A: Long-term dietary cadmium intake
81:191–201, 2002. and postmenopausal endometrial cancer incidence: a popula-
88. Kent MS, Burton JH, Dank G, et al.: Association of cancer- tion-based prospective cohort study, Cancer Res 68:6435–6441,
related mortality, age and gonadectomy in golden retriever dogs 2008.
at a veterinary academic center (1989-2016), PLoS One 13: 110. Shaw J: Relationship-centered approach to cancer communication.
e0192578, 2018. In Withrow SJ, MacEwen EG, Page RL, editors: Small animal clini-
89. Martano M, Morello E, Buracco P: Feline injection-site sarcoma: cal oncology, ed 5, St. Louis, 2012, Elsevier, pp 272–279.
past, present and future perspectives, Vet J 188:136–141, 2011. 111. Raghavan M, Knapp DW, Dawson MH, et al.: Topical flea and
90. Kass PH, Barnes WG, Spangler WL, et al.: Epidemiologic evidence tick pesticides and the risk of transitional cell carcinoma of the uri-
for a causal relation between vaccination and fibrosarcoma tumori- nary bladder in Scottish Terriers, J Am Vet Med Assoc 225:389–394,
genesis in cats, J Am Vet Med Assoc 203:396–405, 1993. 2004.
91. Kass PH, Spangler WL, Hendrick MJ, et al.: Multicenter case-con- 112. Bettini G, Morini M, Marconato L, et al.: Association between
trol study of risk factors associated with development of vaccine- environmental dust exposure and lung cancer in dogs, Vet J
associated sarcomas in cats, J Am Vet Med Assoc 223:1283–1292, 186:364–369, 2010.
2003. 113. Bukowski JA, Wartenberg D, Goldschmidt M: Environmental
92. Kass PH: Methodological issues in the design and analysis of epi- causes for sinonasal cancers in pet dogs, and their usefulness as sen-
demiological studies of feline vaccine-associated sarcomas, Anim tinels of indoor cancer risk, J Toxicol Environ Health A 54:579–591,
Health Res Rev 5:291–293, 2004. 1998.
93. Magden E, Quackenbush SL, Vandewoude S: FIV associated neo- 114. Dias Pereira P, Lopes CC, Matos AJ, et al.: Influence of catechol-
plasms-A mini-review, Vet Immunol Immunopathol 143:227–234, O-methyltransferase (COMT) genotypes on the prognosis of
2011. canine mammary tumors, Vet Pathol 46:1270–1274, 2009.
94. Yamamoto JK, Hansen H, Ho EW, et al.: Epidemiologic and clini- 115. Misdorp W, Romijn A, Hart AA: Feline mammary tumors: a case-
cal aspects of feline immunodeficiency virus infection in cats from control study of hormonal factors, Anticancer Res 11:1793–1797,
the continental United States and Canada and possible mode of 1991.
transmission, J Am Vet Med Assoc 194:213–220, 1989. 116. Overley B, Shofer FS, Goldschmidt MH, et al.: Association
95. Rezanka LJ, Rojko JL, Neil JC: Feline leukemia virus: pathogenesis between ovarihysterectomy and feline mammary carcinoma, J Vet
of neoplastic disease, Cancer Invest 10:371–389, 1992. Intern Med 19:560–563, 2005.
96. Shelton GH, Grant CK, Cotter SM, et al.: Feline immunodefi- 117. Hart BL, Hart LA, Thigpen AP, et al.: Neutering of German Shep-
ciency virus and feline leukemia virus infections and their rela- herd dogs: associated joint disorders, cancers and urinary inconti-
tionships to lymphoid malignancies in cats: a retrospective study nence, Vet Med and Sci 2:191–199, 2016.
(1968-1988), J Acquir Immune Defic Syndr 3:623–630, 1990. 118. Perez Alenza D, Rutteman GR, Pena L, et al.: Relation between
97. Bossuyt PM, Reitsma JB: The STARD initiative, Lancet 361:71, habitual diet and canine mammary tumors in a case-control study,
2003. J Vet Intern Med 12:132–139, 1998.